Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Cash from Financing Activities (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Cash from Financing Activities for 7 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 55.03% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.9 million through Dec 2025, down 54.75% year-over-year, with the annual reading at -$8.9 million for FY2025, 54.75% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$1.7 million at Strata Critical Medical, up from -$1.8 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $333.5 million in Q2 2021, with the low at -$4.2 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $17.4 million, with a median of -$831500.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities surged 1710.0% in 2021, then tumbled 16743.48% in 2024.
  • Over 5 years, Cash from Financing Activities stood at -$3.0 million in 2021, then surged by 68.51% to -$932000.0 in 2022, then soared by 97.53% to -$23000.0 in 2023, then crashed by 16743.48% to -$3.9 million in 2024, then skyrocketed by 55.03% to -$1.7 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$1.7 million, -$1.8 million, and -$1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.